5064142026-04-012026-06-305064142026-06-305064142026-04-012026-06-30in-capmkt:OtherExpenses1Member5064142026-04-012026-06-30in-capmkt:ReportableSegments1Member5064142026-04-012026-06-30in-capmkt:ReportableSegments2Member5064142026-04-012026-06-30in-capmkt:ReportableSegments3Member5064142026-04-012026-06-30in-capmkt:ReportableSegments1Member5064142026-04-012026-06-30in-capmkt:ReportableSegments2Member5064142026-04-012026-06-30in-capmkt:ReportableSegments3Member5064142026-04-012026-06-30in-capmkt:ReportableSegments1Member5064142026-06-30in-capmkt:ReportableSegments1Member5064142026-04-012026-06-30in-capmkt:ReportableSegments2Member5064142026-06-30in-capmkt:ReportableSegments2Member5064142026-04-012026-06-30in-capmkt:ReportableSegments3Member5064142026-06-30in-capmkt:ReportableSegments3Member5064142026-04-012026-06-30in-capmkt:ReportableSegments1Member5064142026-06-30in-capmkt:ReportableSegments1Member5064142026-04-012026-06-30in-capmkt:ReportableSegments2Member5064142026-06-30in-capmkt:ReportableSegments2Member5064142026-04-012026-06-30in-capmkt:ReportableSegments3Member5064142026-06-30in-capmkt:ReportableSegments3Member5064142026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15064142026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss25064142026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares506414FERMENTANOTLISTEDINE225B01021Fermenta Biotech LimitedMain BoardEquity2026-04-012027-03-312026-08-112026-08-04INRLakhsQuarterlyFirst quarterMulti segment2026-08-1111:00:002026-08-1113:10:00Declaration of unmodified opinionfalsefalseDisclosure for the default on loans and debt securities is not applicable to the entity.2026-04-012026-06-30UnauditedStandalone111839300048966000116735900044857600013019000-106256000200515000253910005186100033279500096590100020145800002014580004360900079910005160000001498580000000149858000-5100014980700014340300055.235.13005.235.132 The above unaudited standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 11th August, 2026. The results of the Company are available for investors at www.fermentabiotech.com, www.bseindia.com and www.nseindia.com in accordance with the provision of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 <br /> 3 These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) (’Ind AS’) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). <br /> 4 During the previous year, the Company sold a portion of its investment property comprising freehold land situated at Village Takawe. The gain arising from such sale amounted to Rs.162.89 lakhs for the quarter ended June 30, 2025 and the year ended March 31, 2026 (quarter ended June 30, 2026: Rs. Nil; quarter ended March 31, 2026: Rs. Nil). The said income has been recognized under 'Revenue from Operations' pertaining to the Property Segment. <br /> 5 During the previous year, the Company transferred its Environment Division to its wholly owned subsidiary, Fermenta Environment Solutions Private Limited, as a going concern on a slump sale basis with effect from October 01, 2025, for a consideration of Rs. 1,900 lakhs. <br /> 6 During the current period, the company has consumed semi-finished inventory provided for in the earlier year towards the production of animal feed and accordingly such provision has been reversed for the quarter ended June 30, 2026 is Rs. 205.00 lakhs, (for the quarter ended March 31, 2026 is Rs. 316.78 lakhs , for the quarter ended June 30, 2025 is Rs. Nil lakhs and the year ended March 31, 2026 is Rs. 1,023.73 lakhs). <br /> 7 In the earlier years, the company had recognised provision against certain receivables and trade receivables. The company recovered part amount of Rs. 907.14 lakhs against these provided balances and accordingly such provision reversed and recorded as an exceptional items in the year and quarter ended March 31, 2026. <br /> 8 During the previous year, the Company assessed the potential impact of increased employee benefit obligations arising from the implementation of the Labour Codes, based on its best estimate and in consultation with external experts. Accordingly, the Company recognised a provision of Rs. 210.52 lakhs for the year ended March 31, 2026 in accordance with Ind AS 19, Employee Benefits, which was disclosed as exceptional item. <br /> 9 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the unaudited published year to date figures upto the nine months ended December 31, 2025 which were subjected to a limited review by the statutory auditors. <br /> 10 During the quarter, the Company has granted 3,95,400 employee stock options to the eligible employees of the company at an exercise price of Rs. 83.67 per option exercisable into equivalent equity share of Rs. 5 each subject to the fulfilment of vesting conditions, under "The Fermenta Biotech Limited - Employee Stock Option Scheme 2025", as approved by the shareholders of the Company on 12th August 2025. <br /> 11 Figures of the previous periods have been regrouped/ reclassified wherever necessary to conform to the current period classification. <br /> Other expenses332795000Bulk drugs/chemicals1134196000Property (Refer Note 4)19936000Unallocated (Refer Note 5)13227000116735900001167359000Bulk drugs/chemicals212938000Property (Refer Note 4)684000Unallocated (Refer Note 5)13227000226849000253910000201458000Bulk drugs/chemicals5407500000Property (Refer Note 4)86258000Unallocated (Refer Note 5)1270951000676470900006764709000Bulk drugs/chemicals945118000Property (Refer Note 4)389407000Unallocated (Refer Note 5)1040927000237545200002375452000Net fair value of change in investment in equity instruments-68000Income tax thereon17000-510000-51000UnauditedtrueS R B C & CO LLPtrue2029-02-28